Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-134577
Filing Date
2024-12-09
Accepted
2024-12-09 16:30:05
Documents
5
Period of Report
2024-12-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A nov_24_rdo_sp_mt_proxy_d.htm DEF 14A 220624
2 GRAPHIC img148877704_0.jpg GRAPHIC 78871
3 GRAPHIC img148877704_1.jpg GRAPHIC 5500
4 GRAPHIC img148877704_2.jpg GRAPHIC 1262808
5 GRAPHIC img148877704_3.jpg GRAPHIC 150217
  Complete submission text file 0000950170-24-134577.txt   2280347
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12830 | Film No.: 241535460
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)